AYGESTIN ® (norethindrone acetate tablets, USP)

Manufacturer
Teva Women's Health LLC
Effective date
2015-10-31
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
11
Source
legacy-cache
Hydrated at
2026-08-01 21:20:04

Label at a glance#

ProductAygestin
Active ingredientNORETHINDRONE ACETATE
Label structure11 sections

Indications and uses

AYGESTIN (norethindrone acetate tablets USP) is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN (norethindrone acetate tablets USP) is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for end...

Dosage and administration

Therapy with AYGESTIN must be adapted to the specific indications and therapeutic response of the individual patient. 2.5 to 10 mg AYGESTIN may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen. Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing AYGESTIN therapy....

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

AYGESTIN® (norethindrone acetate tablets USP) - 5 mg oral tablets.

AYGESTIN® (norethindrone acetate tablets USP), (17-hydroxy-19-nor-17α-pregn-4-en-20-yn-3-one acetate), a synthetic, orally active progestin, is the acetic acid ester of norethindrone. It is a white, or creamy white, crystalline powder. The structural formula is as follows:

Norethindrone Acetate structural formula
Norethindrone Acetate structural formula

C22H28O3 M.W. 340.46

AYGESTIN® (norethindrone acetate tablets USP) contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Norethindrone acetate induces secretory changes in an estrogen-primed endometrium. On a weight basis, it is twice as potent as norethindrone.

Pharmacokinetics

PHARMACOKINETICS SECTION

Absorption

SPL UNCLASSIFIED SECTION

Norethindrone acetate is completely and rapidly deacetylated to norethindrone (NET) after oral administration, and the disposition of norethindrone acetate is indistinguishable from that of orally administered norethindrone. Norethindrone acetate is rapidly absorbed from AYGESTIN tablets, with maximum plasma concentration of norethindrone generally occurring at about 2 hours post-dose. The pharmacokinetic parameters of norethindrone following single oral administration of AYGESTIN in 29 healthy female volunteers are summarized in Table 1.

 

Table 1

Pharmacokinetic Parameters after a Single Dose of
AYGESTIN® in Healthy Women

 

AYGESTIN® (n = 29) Arithmetic Mean ± SD

 

Norethindrone (NET)

 

AUC (0-inf)(ng/ml*h)

 

166.90 ± 56.28

 

Cmax (ng/ml)

 

26.19 ± 6.19

 

tmax (h)

 

1.83 ± 0.58

 

t1/2 (h)

 

8.51 ± 2.19

 

AUC = area under the curve,
Cmax = maximum plasma concentration,
tmax = time at maximum plasma concentration,
t1/2 = half-life,
SD = standard deviation

Figure 1. Mean Plasma Concentration Profile after a Single Dose of 5 mg Administered to 29 Healthy Female Volunteers under Fasting Conditions

Figure 1
Figure 1
Effect of Food

SPL UNCLASSIFIED SECTION

The effect of food administration on the pharmacokinetics of AYGESTIN has not been studied.

Distribution

SPL UNCLASSIFIED SECTION

Norethindrone is 36% bound to sex hormone-binding globulin (SHBG) and 61% bound to albumin. Volume of distribution of norethindrone is about 4 L/kg.

Metabolism

SPL UNCLASSIFIED SECTION

Norethindrone undergoes extensive biotransformation, primarily via reduction, followed by sulfate and glucuronide conjugation. The majority of metabolites in the circulation are sulfates, with glucuronides accounting for most of the urinary metabolites.

Excretion

SPL UNCLASSIFIED SECTION

Plasma clearance value for norethindrone is approximately 0.4 L/hr/kg. Norethindrone is excreted in both urine and feces, primarily as metabolites. The mean terminal elimination half-life of norethindrone following a single dose administration of AYGESTIN is approximately 9 hours.

Special Populations

SPL UNCLASSIFIED SECTION

Geriatrics

SPL UNCLASSIFIED SECTION

The effect of age on the pharmacokinetics of norethindrone after AYGESTIN administration has not been evaluated.

Race

SPL UNCLASSIFIED SECTION

The effect of race on the disposition of norethindrone after AYGESTIN administration has not been evaluated.

Renal Insufficiency

SPL UNCLASSIFIED SECTION

The effect of renal disease on the disposition of norethindrone after AYGESTIN administration has not been evaluated. In premenopausal women with chronic renal failure undergoing peritoneal dialysis who received multiple doses of an oral contraceptive containing ethinyl estradiol and norethindrone, plasma norethindrone concentration was unchanged compared to concentrations in premenopausal women with normal renal function.

Hepatic Insufficiency

SPL UNCLASSIFIED SECTION

The effect of hepatic disease on the disposition of norethindrone after AYGESTIN administration has not been evaluated. However, AYGESTIN is contraindicated in markedly impaired liver function or liver disease.

Drug Interactions

SPL UNCLASSIFIED SECTION

No pharmacokinetic drug interaction studies investigating any drug-drug interactions with AYGESTIN have been conducted.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

AYGESTIN (norethindrone acetate tablets USP) is indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. AYGESTIN (norethindrone acetate tablets USP) is not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

  • Known or suspected pregnancy. There is no indication for AYGESTIN in pregnancy. (See PRECAUTIONS.)
  • Undiagnosed vaginal bleeding
  • Known, suspected or history of cancer of the breast
  • Active deep vein thrombosis, pulmonary embolism or history of these conditions
  • Active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial infarction)
  • Impaired liver function or liver disease
  • As a diagnostic test for pregnancy
  • Hypersensitivity to any of the drug components

WARNINGS

WARNINGS SECTION

  1. Cardiovascular Disorders
    Patients with risk factors for arterial vascular disease (e.g., hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (e.g., personal history or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
  2. Visual Abnormalities
    Discontinue medication pending examination if there is a sudden partial or complete loss of vision or if there is sudden onset of proptosis, diplopia, or migraine. If examination reveals papilledema or retinal vascular lesions, medication should be discontinued.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

  • Because this drug may cause some degree of fluid retention, conditions which might be influenced by this factor, such as epilepsy, migraine, cardiac or renal dysfunctions, require careful observation.
  • In cases of breakthrough bleeding, and in all cases of irregular bleeding per vagina, nonfunctional causes should be borne in mind. In cases of undiagnosed vaginal bleeding, adequate diagnostic measures are indicated.
  • Patients who have a history of clinical depression should be carefully observed and the drug discontinued if the depression recurs to a serious degree.
  • Data suggest that progestin therapy may have adverse effects on lipid and carbohydrate metabolism. The choice of progestin, its dose, and its regimen may be important in minimizing these adverse effects, but these issues will require further study before they are clarified. Women with hyperlipidemias and/or diabetes should be monitored closely during progestin therapy.
  • The pathologist should be advised of progestin therapy when relevant specimens are submitted.

Information for the Patient

INFORMATION FOR PATIENTS SECTION

Healthcare providers are advised to discuss the PATIENT INFORMATION leaflet with patients for whom they prescribe AYGESTIN.

Drug/Laboratory Tests Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

The following laboratory test results may be altered by the use of estrogen/progestin combination drugs:

  1. Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity.
  2. Increased thyroid-binding globulin (TBG) levels leading to increased circulating total thyroid hormone levels as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Patients on thyroid replacement therapy may require higher doses of thyroid hormone.
  3. Other binding proteins may be elevated in serum (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased circulating corticosteroid and sex steroids, respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin).
  4. Increased plasma HDL and HDL2 cholesterol subfraction concentrations, reduced LDL cholesterol concentration, increased triglycerides levels.
  5. Impaired glucose metabolism.
  6. Reduced response to metyrapone test.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Some beagle dogs treated with medroxyprogesterone acetate developed mammary nodules. Although nodules occasionally appeared in control animals, they were intermittent in nature, whereas nodules in treated animals were larger and more numerous, and persisted. There is no general agreement as to whether the nodules are benign or malignant. Their significance with respect to humans has not been established.

Pregnancy

PREGNANCY SECTION

Category X

SPL UNCLASSIFIED SECTION

Norethindrone acetate is contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. Several reports suggest an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and congenital abnormalities in male and female fetuses. Some progestational drugs induce mild virilization of the external genitalia of female fetuses.

Nursing Mothers

NURSING MOTHERS SECTION

Detectable amounts of progestins have been identified in the milk of mothers receiving them. Caution should be exercised when progestins are administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

AYGESTIN tablets are not indicated in children.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

See WARNINGS and PRECAUTIONS.

The following adverse reactions have been observed in women taking progestins:

  • Breakthrough bleeding
  • Spotting
  • Change in menstrual flow
  • Amenorrhea
  • Edema
  • Changes in weight (decreases, increases)
  • Changes in the cervical squamo-columnar junction and cervical secretions
  • Cholestatic jaundice
  • Rash (allergic) with and without pruritus
  • Melasma or chloasma
  • Clinical depression
  • Acne
  • Breast enlargement/tenderness
  • Headache/migraine
  • Urticaria
  • Abnormalities of liver tests (i.e., AST, ALT, Bilirubin)
  • Decreased HDL cholesterol and increased LDL/HDL ratio
  • Mood swings
  • Nausea
  • Insomnia
  • Anaphylactic/anaphylactoid reactions
  • Thrombotic and thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, retinal vascular thrombosis, cerebral thrombosis and embolism)
  • Optic neuritis (which may lead to partial or complete loss of vision)

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Therapy with AYGESTIN must be adapted to the specific indications and therapeutic response of the individual patient.

Secondary amenorrhea, abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology

SPL UNCLASSIFIED SECTION

2.5 to 10 mg AYGESTIN may be given daily for 5 to 10 days to produce secretory transformation of an endometrium that has been adequately primed with either endogenous or exogenous estrogen.

Progestin withdrawal bleeding usually occurs within three to seven days after discontinuing AYGESTIN therapy. Patients with a past history of recurrent episodes of abnormal uterine bleeding may benefit from planned menstrual cycling with AYGESTIN.

Endometriosis

SPL UNCLASSIFIED SECTION

Initial daily dosage of 5 mg AYGESTIN for two weeks. Dosage should be increased by 2.5 mg per day every two weeks until 15 mg per day of AYGESTIN is reached. Therapy may be held at this level for six to nine months or until annoying breakthrough bleeding demands temporary termination.

HOW SUPPLIED

HOW SUPPLIED SECTION

AYGESTIN® (norethindrone acetate tablets USP) is available as:

 

5 mg:

 

White, oval, flat-faced, beveled edge, tablet scored on one side. Debossed with 5 AYGESTIN on the unscored side and stylized b / 424 on the scored side. Available in bottles of 50 tablets (NDC 51285-424-10).

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).

Store at 20º to 25ºC (68º to 77ºF) [See USP Controlled Room Temperature].

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

TEVA WOMEN’S HEALTH, INC.

Subsidiary of TEVA PHARMACEUTICALS USA, INC.
North Wales, PA 19454

Rev. A 10/2015

PATIENT INFORMATION

SPL PATIENT PACKAGE INSERT SECTION

AYGESTIN®
(norethindrone acetate tablets USP)

Read this PATIENT INFORMATION before you start taking AYGESTIN and read what you get each time you refill AYGESTIN. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition.

What is the most important information I should know about AYGESTIN (A Progestin Hormone)?

  • Do not use AYGESTIN if you are pregnant, breastfeeding or are trying to conceive.
  • Do not use AYGESTIN if you have had a previous blood clot, stroke, or heart attack.
  • Do not use AYGESTIN if you are postmenopausal.

What is AYGESTIN?

AYGESTIN is similar to the progesterone hormones naturally produced by the body. Your healthcare provider may provide AYGESTIN as individual tablets.

What are AYGESTIN used for?

AYGESTIN are used for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously had a menstrual period who are not pregnant), the treatment of endometriosis, and the treatment of irregular menstrual periods due to hormone imbalance.

Who should not take AYGESTIN?

You should not take AYGESTIN if you are postmenopausal, pregnant or breastfeeding.

You should not take AYGESTIN if you have the following conditions:

  • Known or suspected pregnancy. AYGESTIN are not indicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take AYGESTIN during the first 4 months of pregnancy (mild masculinization of the external genitalia of the female fetus, as well as hypospadias in the male fetus). If you take AYGESTIN and later find out you were pregnant, talk with your healthcare provider right away.
  • History of blood clots in the legs, lungs, eyes, brain, or elsewhere, or a past history of these conditions
  • Liver impairment or disease
  • Known or suspected cancer of the breast. If you have or had cancer of the breast, talk with your healthcare provider about whether you should take AYGESTIN.
  • Undiagnosed vaginal bleeding
  • Hypersensitivity to AYGESTIN. See the end of this leaflet for a list of all of the ingredients in AYGESTIN.

What are the risks associated with AYGESTIN?

  • Risk to the Fetus

AYGESTIN should not be used if you are pregnant. AYGESTIN are contraindicated during pregnancy as it may cause fetal harm when administered to pregnant women. There is an increased risk of minor birth defects in children whose mothers take this drug during the first 4 months of pregnancy. Several reports suggest an association between mothers who take these drugs in the first trimester of pregnancy and congenital abnormalities in male and female babies. Although it is not clear that these events were drug related, you should check with your healthcare provider about the risks to your unborn child of any medication taken during pregnancy.

You should avoid using AYGESTIN during pregnancy. If you take AYGESTIN and later find you were pregnant when you took it, be sure to discuss this with your healthcare provider as soon as possible.

  • Abnormal Blood Clotting

Use of progestational drugs, such as AYGESTIN, has been associated with changes in the blood-clotting system. These changes allow the blood to clot more easily, possibly allowing clots to form in the bloodstream. If blood clots do form in your bloodstream, they can cut off the blood supply to vital organs, causing serious problems. These problems may include a stroke (by cutting off blood to part of the brain), a heart attack (by cutting off blood to part of the heart), a pulmonary embolus (by cutting off blood to part of the lungs), visual loss or blindness (by cutting off blood vessels in the eye), or other problems. Any of these conditions may cause death or serious long-term disability. Call your healthcare provider right away if you suspect you have any of these conditions. He or she may advise you to stop using the drug.

  • Eye Abnormalities

Discontinue AYGESTIN tablets and call your healthcare provider right away if you experience sudden partial or complete loss of vision, blurred vision, or sudden onset of bulging eyes, double vision, or migraine.

These are some of the warning signs of serious side effects with progestin therapy

  • Breast lumps
  • Dizziness and faintness
  • Changes in speech
  • Severe headaches
  • Chest pain
  • Shortness of breath
  • Pains in your legs
  • Changes in vision

Call your healthcare provider right away if you get any of these warning signs, or any other unusual symptom that concerns you.

Common side effects include

  • Headache
  • Breast pain
  • Irregular vaginal bleeding or spotting
  • Stomach/abdominal cramps/bloating
  • Nausea and vomiting
  • Hair loss

Other side effects include

  • High blood pressure
  • Liver problems
  • High blood sugar
  • Fluid retention
  • Enlargements of benign tumors of the uterus (“fibroids”)
  • Vaginal yeast infections
  • Mental depression

These are not all the possible side effects of progestin and/or estrogen therapy. For more information, ask your healthcare provider or pharmacist.

What can I do to lower my chances of getting a serious side effect with AYGESTIN?

  • Talk with your healthcare provider regularly about whether you should continue taking AYGESTIN.
  • Have a breast exam and mammogram (breast x-ray) every year unless your healthcare provider tells you something else. If members of your family have had breast cancer or if you have ever had breast lumps or an abnormal mammogram, you may need to have breast exams more often.
  • If you have high blood pressure, high cholesterol (fat in the blood), diabetes, are overweight, or if you use tobacco, you may have higher chances for getting heart disease. Ask your healthcare provider for ways to lower your chances of getting heart attacks.

General information about the safe and effective use of AYGESTIN

Medicines are sometimes prescribed for conditions that are not mentioned in patient information leaflets. Do not take AYGESTIN for conditions for which it was not prescribed. Do not give AYGESTIN tablets to other people, even if they have the same symptoms you have. It may harm them.

Keep AYGESTIN out of the reach of children.

This leaflet provides a summary of the most important information about progestin and/or estrogen therapy. If you would like more information, talk with your healthcare provider or pharmacist. You can ask for information about AYGESTIN that is written for health professionals.

What are the ingredients in AYGESTIN?

AYGESTIN contain the following inactive ingredients: anhydrous lactose, magnesium stearate, and microcrystalline cellulose.

TEVA WOMEN’S HEALTH, INC.

Subsidiary of TEVA PHARMACEUTICALS USA, INC.
North Wales, PA 19454

Rev. A 10/2015

Package/Label Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 51285-424-10

Aygestin®

(norethindrone acetate

tablets USP)

ORALLY ACTIVE PROGESTIN

5 mg

PHARMACIST: PLEASE DISPENSE WITH
ATTACHED PATIENT INFORMATION LEAFLET.

Rx only

50 TABLETS

TEVA WOMEN’S HEALTH

Package/Label Display Panel
Package/Label Display Panel

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
51285-424-10EA - Each51285-424014ea00c-51f0-43b4-a950-e2cd8fbd110a12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
NORETHINDRONE ACETATEACTIVE INGREDIENT9S44LIC7OJ5
NORETHINDRONEACTIVE MOIETYT18F433X4S5
ANHYDROUS LACTOSEINACTIVE INGREDIENT3SY5LH9PMK5
CELLULOSE, MICROCRYSTALLINEINACTIVE INGREDIENTOP1R32D61U5
MAGNESIUM STEARATEINACTIVE INGREDIENT70097M6I305

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 6 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
51285-42451285-424-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 88 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKCAPSULE / ORAL2490 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, FILM COATED / ORAL992 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL1576 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UGRANULE, DELAYED RELEASE / ORAL789.6 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30IMPLANT / SUBCUTANEOUS0.5 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, EXTENDED RELEASE / ORAL5119 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SYSTEM / INTRAVITREAL0.02 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, FILM COATED, EXTENDED RELEASE / ORAL53 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, COATED / ORAL560 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UCAPSULE, DELAYED RELEASE / ORAL366 mgExact identifier — unii candidate
28 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKINJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR25 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, COATED / ORAL184 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UPOWDER, FOR SOLUTION / ORAL690 mgExact identifier — unii candidate
28 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, EXTENDED RELEASE / ORAL529 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UCAPSULE, COATED PELLETS / ORAL456 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER, FOR SUSPENSION / ORAL120 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30RING / VAGINAL2 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKCAPSULE, EXTENDED RELEASE / ORAL869 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UIMPLANT / INTRAVITREAL1.66 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION / ORAL64 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30SUSPENSION, EXTENDED RELEASE / ORAL71 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, FOR SUSPENSION / ORAL131 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30POWDER / TOPICAL104 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKCAPSULE, DELAYED RELEASE / ORAL360 mgExact identifier — unii candidate
21 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET / SUBLINGUAL128 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UGRANULE, FOR SUSPENSION / ORAL278 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UCAPSULE / ORAL2169 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30DROPS / ORALNAExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTROCHE / ORAL300 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, DELAYED RELEASE / ORAL144 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE / ORAL629 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, ORALLY DISINTEGRATING / ORAL1800 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, EXTENDED RELEASE / ORAL117 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, CHEWABLE / ORAL1725 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30WAFER / ORAL66 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, FOR SUSPENSION / ORAL20100 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE / ORAL256.4 mgExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS25 mgExact identifier — unii candidate
21 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, FILM COATED / ORAL96 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30GRANULE, FOR SUSPENSION / ORAL14 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING / ORAL187 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / SUBLINGUAL43.2 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, DELAYED RELEASE / ORAL2210 mgExact identifier — unii candidate
28 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKSUSPENSION / ORAL15.69 mg/5mlExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UGRANULE / ORAL29520 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, DELAYED RELEASE / ORAL1060 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30IMPLANT / INTRAVITREALNAExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET / ORAL6795 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UPELLET / ORAL1140 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET / BUCCAL18 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL47 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30TROCHE / ORAL315 mgExact identifier — unii candidate
39 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30INHALANT / ORAL0.08 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UTABLET, COATED / ORAL920 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30CAPSULE, COATED, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
39 equally ranked IID candidates
ANHYDROUS LACTOSEANHYDROUS LACTOSE3SY5LH9PMKTABLET, DELAYED RELEASE / ORAL1083 mgExact identifier — unii candidate
21 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61USUSPENSION, EXTENDED RELEASE / ORAL1120 mgExact identifier — unii candidate
28 equally ranked IID candidates
MAGNESIUM STEARATEMAGNESIUM STEARATE70097M6I30INSERT / VAGINAL69 mgExact identifier — unii candidate
39 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61UPOWDER, FOR SUSPENSION / ORAL4441 mgExact identifier — unii candidate
28 equally ranked IID candidates
CELLULOSE, MICROCRYSTALLINEMICROCRYSTALLINE CELLULOSEOP1R32D61USUSPENSION / ORAL1600 mgExact identifier — unii candidate
28 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A075951-001NORETHINDRONE ACETATENORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A075951-001AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25c2088c7a36db…
2026-09-14 22:38:342026-08A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2584e616aacf4f…
2026-08-18 06:07:402026-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2531067a03dcf5…
2025-08-23 18:47 UTC2025-08A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-256a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2503ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-252680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2579d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-251e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-258072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-254b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2574a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-2587673890dc5c…
2021-03-12 10:30 UTC2021-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-255aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-258869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253f01610625f2…
2019-09-15 20:21 UTC2019-09A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25b00525d2431f…
2019-07-19 19:46 UTC2019-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-256a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-251c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-259b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253f0d92c62455…
2023-05-13 08:27 UTC2023-05A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-25053a50430f4f…
2023-01-26 05:58 UTC2023-01A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075951-001NORETHINDRONE ACETATE5MGTABLET / ORALABRS2001-05-253a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A075951-001AB1c2088c7a36db…
2026-09-14 22:38:342026-08A075951-001AB184e616aacf4f…
2026-08-18 06:07:402026-07A075951-001AB1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A075951-001AB1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A075951-001AB131067a03dcf5…
2025-08-23 18:47 UTC2025-08A075951-001AB16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A075951-001AB1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A075951-001AB1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A075951-001AB103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A075951-001AB12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A075951-001AB15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A075951-001AB1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A075951-001AB1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A075951-001AB179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A075951-001AB1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A075951-001AB11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A075951-001AB18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A075951-001AB15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A075951-001AB15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A075951-001AB14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A075951-001AB174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A075951-001AB1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A075951-001AB1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A075951-001AB187673890dc5c…
2021-03-12 10:30 UTC2021-03A075951-001AB15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A075951-001AB18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A075951-001AB1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A075951-001AB13f01610625f2…
2019-09-15 20:21 UTC2019-09A075951-001AB1b00525d2431f…
2019-07-19 19:46 UTC2019-07A075951-001AB1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A075951-001AB16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A075951-001AB11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A075951-001AB1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A075951-001AB1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A075951-001AB19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A075951-001AB1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A075951-001AB13f0d92c62455…
2023-05-13 08:27 UTC2023-05A075951-001AB1053a50430f4f…
2023-01-26 05:58 UTC2023-01A075951-001AB13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A075951-001AB13a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
8cfac7d2-c6b7-4211-93b6-46441b1ba0e969f5bc4b-758d-471b-ad8d-17c94f8e09632015-10-31Warnings, Adverse reactionsExact identifier
spl id: 8cfac7d2-c6b7-4211-93b6-46441b1ba0e9
spl set id: 69f5bc4b-758d-471b-ad8d-17c94f8e0963

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.